capreomycin IB   Click here for help

GtoPdb Ligand ID: 13256

Synonyms: Capastat®
Approved drug
capreomycin IB is an approved drug (UK, FDA (1971))
Comment: Capreomycin is a tuberactinomycin antibacterial, originally isolated from cultures of Streptomyces capreolus as a mixture of four components (capreomycins IA, IB, IIA, and IIB) [2]. We show the structure for capreomycin IB, a cyclic depsipeptide, which is reported to be the major component of capreomycin [1]. Note that the INN describes a mixture of capreomycin IA and IB, represented by PubChem CID 3000502.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 21
Hydrogen bond donors 13
Rotatable bonds 11
Topological polar surface area 358.19
Molecular weight 652.71
XLogP -3.74
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@H]1C(=O)N[C@@H](CNC(=O)C[C@H](CCCN)N)C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@@H]([C@H]2CCNC(=N2)N)C(=O)NC[C@@H](C(=O)N1)N
Isomeric SMILES C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCNC(=N2)N)CNC(=O)C[C@H](CCCN)N
InChI InChI=1S/C25H44N14O7/c1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b16-10+/t11-,12-,13-,14+,15-,18-/m0/s1
InChI Key FRXNXDHFQYZYNA-OJBVOROPSA-N
No information available.
Summary of Clinical Use Click here for help
The formulation of capreomycin that entered clinical use was a mixture of all four components. Injectable capreomycin sulfate was approved by the USA FDA in 1971 (under the trade name Capastat®) but is now discontinued. It is indicated for use in the treatment of pulmonary tuberculosis caused by capreomycin-sensitive strains of Mycobacterium tuberculosis when first-line drugs cannot be used.
It was removed from the World Health Organization's List of Essential Medicines in 2019, due to increased treatment failure and toxicity when compared to alternative available therapies.
External links Click here for help